[Correlation analysis on single nucleotide polymorphism of IL-23 receptor gene to susceptibility and clinical efficacy of recurrent oral ulcer].

PURPOSE:To investigate the correlation of gene polymorphisms of interleukin-23 receptor (IL-23R) rs11465817 and rs10489629 loci to susceptibility and clinical efficacy of recurrent oral ulcer (ROU). METHODS:A total of 150 ROU patients, who visited Stomatological Department of our hospital from January 2016 to December 2018, were selected as ROU group. A total of 150 healthy subjects who underwent physical examination at the same time in our hospital, were selected as healthy control group. Blood DNA was extracted from all subjects and amplified by polymerase chain reaction (PCR) at sites of IL-23R rs11465817 and rs10489629 loci. The genotyping was determined by electrophoresis after enzymatic digestion of amplified products. Patients with ROU were treated with oral levamisole, vitamin C, vitamin B2 and cetylpyridnium chloride gargle. Ulcer area and pain index were used to evaluate the clinical efficacy before and in the first week after treatment. Correlation on gene polymorphisms of interleukin-23 receptor (IL-23R) rs11465817 and rs10489629 loci to susceptibility and clinical efficacy of ROU was analyzed. SPSS 22.0 software package was used for statistical analysis of the data. RESULTS:Genotyping distribution of IL-23R rs11465817 and il-23r rs10489629 loci in healthy control group met Hardy-Weinberg equilibrium (P>0.05). Distribution frequency of CC and CA genotypes of IL-23R rs11465817 loci in ROU group was significantly higher than that in healthy control group (P<0.05), and logistic regression analysis showed that ROU risk in patients with CC and CA genotypes was significantly higher (P<0.05). The genotyping frequency of IL-23R rs10489629 loci was not significantly different between both groups (P>0.05). Logistic regression analysis showed that genotyping of IL-23R rs10489629 loci was not correlated with ROU sensitivity (P>0.05). The mean ulcer area and VAS score of ROU patients was significantly reduced after treatment (P<0.05). The ulcer area and VAS score in patients with IL-23R rs11465817 loci of AA genotype was significantly lower than that in patients with IL-23R rs11465817 loci of CC or CA genotype (P<0.05). Ulcer area and VAS score in patients with IL-23R rs10489629 locus of each genotype was not significantly different (P>0.05). CONCLUSIONS:Polymorphism of IL-23R rs11465817 loci is probably related to susceptibility and clinical efficacy of ROU, while polymorphism of IL-23R rs 10489629 is not probably related to susceptibility and clinical efficacy of ROU. The results of this study need to be further validated by a clinical study with large sample size.

KEYWORDS: {{ getKeywords(articleDetailText.words) }}